SR 146131

a cholecystokinin subtype 1 receptor agonist; structure in first source

Also Known As:

2-(4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)thiazol-2-ylcarbamoyl)-5,7-dimethylindol-1-yl-1-acetic acid; SR-146131; SR146131

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

1.	Motor Disorders 05/01/1999 - "Because pharmacodynamic studies suggest that SR146131 should have a high absolute bioavailability, it may be a promising drug for the treatment of eating and motor disorders in humans."
2.	Neuroblastoma 06/02/2000 - "Characterisation of the effects of SR146131, a novel non-peptide CCK(1) receptor agonist, on IMR-32 human neuroblastoma cells." 05/01/1999 - "In the human CHP212 and IMR32 neuroblastoma cell lines, which constitutively express the CCK1 receptor, SR146131 behaved as a partial agonist on intracellular calcium release and inositol monophosphate formation. " 06/02/2000 - "The effect of ¿2-[4-(4-chloro-2, 5-dimethoxy-phenyl)-5-[2-cyclohexyl-ethyl)-thiazol-2-ylcarbamoy l]-5, 7-dimethyl-indol-1-yl¿-acetic acid (SR146131), a novel non-peptide agonist of cholecystokinin (CCK) CCK(1) receptors, was compared to the effect of sulphated cholecystokinin octapeptide (CCK-8-S) on CCK(1) receptors of the human neuroblastoma cell line IMR-32. "

1.	Cholecystokinin A Receptor
2.	Acetic Acid (Vinegar)
3.	Sincalide
4.	Peptides (Polypeptides)
5.	Inositol (Myoinositol)
6.	Cholecystokinin (Pancreozymin)
7.	Calcium